Literature DB >> 12794582

Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases.

Aali J Sheen1, Joely Irlam, Natalia Kirillova, Ryan D Guest, David J Sherlock, Robert E Hawkins, David E Gilham.   

Abstract

PURPOSE: The overall aim of this study was to develop a novel treatment for colorectal cancer based on the use of gene therapy. Genetic modification of T lymphocytes has been used to specifically target and kill tumor cell lines directly. To test the efficacy of this method with clinically relevant materials, this study investigated the potential of T lymphocytes derived from patients with advanced colorectal disease to target autologous primary tumor material. METHODS T lymphocytes isolated preoperatively were modified genetically with recombinant retroviruses encoding CD3zeta-based chimeric immune receptors and were tested for functional activity against freshly isolated autologous tumor cells harvested from hepatic colorectal metastases.
RESULTS: Patient-derived T cells were successfully transduced, and chimeric immune receptor expression was confirmed. Carcinoembryonic antigen expression on freshly isolated colorectal tumor cells was also demonstrated by molecular and immunohistochemical techniques. T cells expressing the anticarcinoembryonic antigen receptor were specifically activated by coculture with disaggregated or intact, diced tumor, whereas control non-carcinoembryonic antigen-targeted T-cell populations failed to activate.
CONCLUSIONS: These results indicate that gene-targeted primary T lymphocytes depict specific functional activity against autologous colorectal tumor cells. This evidence indicates that chimeric immune receptor-expressing T cells may be able to circumvent the mechanisms used by tumor cells to avoid immune cell activity in vivo. This study emphasizes the potential of this approach as a therapy for carcinoembryonic antigen-expressing primary colorectal tumor and its metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794582     DOI: 10.1007/s10350-004-6659-1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 2.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

3.  Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells.

Authors:  Claudia Schlimper; Andreas A Hombach; Hinrich Abken; Ingo G H Schmidt-Wolf
Journal:  Clin Dev Immunol       Date:  2012-03-19

4.  The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Authors:  Fiona C Thistlethwaite; David E Gilham; Ryan D Guest; Dominic G Rothwell; Manon Pillai; Deborah J Burt; Andrea J Byatte; Natalia Kirillova; Juan W Valle; Surinder K Sharma; Kerry A Chester; Nigel B Westwood; Sarah E R Halford; Stephen Nabarro; Susan Wan; Eric Austin; Robert E Hawkins
Journal:  Cancer Immunol Immunother       Date:  2017-06-28       Impact factor: 6.968

Review 5.  Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.

Authors:  Daniel Sur; Andrei Havasi; Calin Cainap; Gabriel Samasca; Claudia Burz; Ovidiu Balacescu; Iulia Lupan; Diana Deleanu
Journal:  J Clin Med       Date:  2020-01-09       Impact factor: 4.241

6.  Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.

Authors:  R W Griffiths; D E Gilham; A Dangoor; V Ramani; N W Clarke; P L Stern; R E Hawkins
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.